TY - JOUR
T1 - A disease-specific score for estimating survival after irradiation of bone metastases from colorectal cancer
AU - Haus, Rapha
AU - Janssen, Stefan
AU - Schild, Steven E.
AU - Rades, Dirk
N1 - Publisher Copyright:
© 2020 International Institute of Anticancer Research. All rights reserved.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Background/Aim: Estimating survival is important for treatment personalization in patients with metastatic cancer. In this study, we aimed to develop a survival score for patients irradiated for bone metastases from colorectal cancer. Patients and Methods: Eleven factors were retrospectively analyzed in 25 patients, including age, gender, Eastern Cooperative Oncology Group performance score, tumor site, time between diagnosis of colorectal cancer and irradiation, visceral or other bone metastases, type and number of irradiated sites, upfront surgery and previous systemic treatment. Results: On multivariate analysis, performance score (p=0.005) and previous systemic treatment (p=0.007) were significantly associated with survival and used for the score. One point (performance score 0-1 or no previous systemic treatment) or 0 points (performance score ≥2 or previous systemic treatment) were assigned resulting in 0, 1 or 2 points. Six-month survival rates of these groups were 0%, 64% and 100%, respectively. Conclusion: This new survival score can support physicians during personalization of treatment for patients with bone metastases from colorectal cancer.
AB - Background/Aim: Estimating survival is important for treatment personalization in patients with metastatic cancer. In this study, we aimed to develop a survival score for patients irradiated for bone metastases from colorectal cancer. Patients and Methods: Eleven factors were retrospectively analyzed in 25 patients, including age, gender, Eastern Cooperative Oncology Group performance score, tumor site, time between diagnosis of colorectal cancer and irradiation, visceral or other bone metastases, type and number of irradiated sites, upfront surgery and previous systemic treatment. Results: On multivariate analysis, performance score (p=0.005) and previous systemic treatment (p=0.007) were significantly associated with survival and used for the score. One point (performance score 0-1 or no previous systemic treatment) or 0 points (performance score ≥2 or previous systemic treatment) were assigned resulting in 0, 1 or 2 points. Six-month survival rates of these groups were 0%, 64% and 100%, respectively. Conclusion: This new survival score can support physicians during personalization of treatment for patients with bone metastases from colorectal cancer.
UR - http://www.scopus.com/inward/record.url?scp=85077464992&partnerID=8YFLogxK
U2 - 10.21873/anticanres.13951
DO - 10.21873/anticanres.13951
M3 - Journal articles
C2 - 31892578
AN - SCOPUS:85077464992
SN - 0250-7005
VL - 40
SP - 287
EP - 291
JO - Anticancer Research
JF - Anticancer Research
IS - 1
ER -